Stock ALBPS BIOPHYTIS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Biophytis S.A. Euronext Paris

Equities

ALBPS

FR0012816825

Biotechnology & Medical Research

End-of-day quote Euronext Paris
Other stock markets
 06:00:00 2024-05-06 pm EDT 		5-day change 1st Jan Change
0.85 EUR 0.00% Intraday chart for Biophytis S.A. +1.19% -58.33%
May. 14 Biophytis unveils design for obesity study CF
May. 14 Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 91.84 62.22 7.534 3.635 2.231 - -
Enterprise Value (EV) 1 91.84 62.22 7.534 3.635 2.231 2.231 2.231
P/E ratio -3.29 x -1.9 x - - - - -
Yield - - - - - - -
Capitalization / Revenue - - - - - 0.46 x 0.12 x
EV / Revenue - - - - - 0.46 x 0.12 x
EV / EBITDA - - -0.33 x - -0.15 x -0.16 x -0.41 x
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 249 314 409 1,782 2,861 - -
Reference price 2 368.4 198.0 18.40 2.040 0.7800 0.7800 0.7800
Announcement Date 3/12/21 4/7/22 4/19/23 4/8/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - 4.8 18.7
EBITDA 1 - - -22.79 - -14.8 -13.9 -5.4
EBIT 1 - -26.82 -23.27 -14.33 -14.8 -13.9 -5.4
Operating Margin - - - - - -289.58% -28.88%
Earnings before Tax (EBT) 1 - -31.25 -24.22 -17.03 -19.8 -16.9 -8.4
Net income 1 -17.05 -31.25 -24.22 -17.03 -19.8 -16.9 -8.4
Net margin - - - - - -352.08% -44.92%
EPS -112.0 -104.0 - - - - -
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 3/12/21 4/7/22 4/19/23 4/8/24 - - -
1EUR in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 - - - - - - - -
EBITDA 1 - - -11.77 -11.02 -6.268 - -6.5 -8.3
EBIT - - - - - - - -
Operating Margin - - - - - - - -
Earnings before Tax (EBT) 1 - -18 -12.4 -11.82 -7.764 - -7.8 -12.1
Net income 1 -15.86 -18 -12.4 -11.82 -7.764 - -7.8 -12.1
Net margin - - - - - - - -
EPS -56.00 -56.00 -32.00 - - - - -
Dividend per Share - - - - - - - -
Announcement Date 9/17/21 4/7/22 1/31/23 4/19/23 9/27/23 4/8/24 - -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 3/12/21 4/7/22 4/19/23 4/8/24 - - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+8.10% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+13.04% 107B
BIONTECH SE Stock BioNTech SE
-12.93% 22.31B
ARGENX SE Stock argenx SE
-3.99% 21.6B
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.52% 18.23B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.93% 17.62B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.04% 14.26B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.33% 12.37B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-28.58% 8.28B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALBPS Stock
  4. ALBPS Stock
  5. Financials Biophytis S.A.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW